We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Results of a BoNT/A Antibody Study in Children and Adolescents after Onabotulinumtoxin A (Botox®) Detrusor Injection.
- Authors
Schulte-Baukloh, H.; Herholz, J.; Bigalke, H.; Miller, K.; Knispel, H.H.
- Abstract
Background: Onabotulinumtoxin A (OnaBoNT/A, Botox®) is effective in the treatment of neurogenic detrusor overactivity, however this therapy can fail. In a prospective study, we analyzed patient serum for BoNT/A antibodies (BoNT/A-AB) as a possible cause of therapy failure. Methods: 17 patients (average age 14.5 years) who had neurogenic detrusor overactivity were admitted for repeated OnaBoNT/A injection into the detrusor muscle. We analyzed their serum for BoNT/A-AB. The clinical findings were correlated with the incidence of BoNT/A-AB. Results: Positive BoNT/A-AB were clearly or marginally determined in 6 patients. Therapy had failed in all 6. In 4 of the 6, therapy might have failed because of a low-compliance bladder (3 patients) or tethered-cord syndrome (1), but BoNT/A-AB were found as the only possible cause in 2 patients. Thus, the incidence of BoNT/A-AB in the 17 patients was 35%, and the antibodies were clinically significant in 12%. All patients with BoNT/A-AB had a history of recurrent urinary tract infections. Conclusions: Patients who show a failure of therapy after OnaBoNT/A injections for which no other causes can be determined should have their serum checked for BoNT/A-AB. Recurrent urinary tract infection might be a predisposing factor for BoNT/A-AB. Copyright © 2011 S. Karger AG, Basel
- Subjects
OVERACTIVE bladder; BOTULINUM toxin; INJECTIONS; IMMUNOGLOBULINS; LONGITUDINAL method; URINARY incontinence; URINARY tract infections; THERAPEUTICS
- Publication
Urologia Internationalis, 2011, Vol 87, Issue 4, p434
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000331726